Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 299 across all filing types
Latest filing 2026-06-19 Board/Management Inform…
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Zgłoszenie kandydatury
Board/Management Information Classification · 95% confidence The document is a formal nomination submission for a candidate to the Supervisory Board of Bioceltix S.A. It includes the candidate's background, the nominating shareholder's details, and is related to an agenda item of an upcoming General Meeting. It does not contain financial statements, audit information, or results of shareholder voting. This type of document corresponds to announcements regarding board or management changes or nominations. Therefore, it falls under Board/Management Information (MANG). The document length and content do not align with AGM materials or proxy statements and do not announce voting results. Hence, the best classification is MANG with high confidence.
2026-06-19 Polish
Życiorys zawodowy kandydata
Board/Management Information Classification · 95% confidence The document is a professional biography (życiorys zawodowy) of Szymon Ruta, detailing his education and management experience including roles in finance and M&A within various companies. It does not contain financial results, regulatory announcements, voting results, or any form of report. It is an announcement related to board or management personnel, providing information about an individual in a senior position within the company. Thus, it fits the category of Board/Management Information (MANG). The document is short and focused on management details rather than financial disclosures or regulatory filings.
2026-06-19 Polish
Zgłoszenie kandydata na członka Rady Nadzorczej - Content (PL)
Board/Management Information Classification · 95% confidence The document is a brief announcement from Bioceltix S.A. concerning the nomination of a candidate for the Supervisory Board (Rada Nadzorcza). It includes the candidate's resume and statement of consent. The context is linked to an upcoming Annual General Meeting, but this document itself is a shareholder proposal notification related to board composition. The document does not include detailed meeting materials, full biographies for AGM presentations, or financial information, and it is succinct (934 characters). Therefore, it is best classified under Board/Management Information (MANG), as it pertains to announcing changes or nominations in the board of directors.
2026-06-19 Polish
Otrzymanie decyzji o pozwoleniu na budowę dla inwestycji pn. "Wytwórnia biologicznych leków weterynaryjnych" - Content (PL)
Regulatory Filings Classification · 75% confidence The document is an official corporate announcement detailing the receipt of a building permit (“pozwolenia na budowę”) for a new investment by the company. It does not contain financial statements or earnings results, nor does it relate to board changes, dividends, M&A, or shareholder votes. It is a regulatory/current report informing the market about a material event. Therefore it best fits the fallback category “Regulatory Filings (RNS).”
2026-06-09 Polish
4. Wniosek Akcjonariusza o rozszerzenie porządku obrad Walnego Zgromadzenia
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a formal shareholder submission addressed to the Management Board of Bioceltix S.A. (an Ordinary General Meeting scheduled for June 23, 2026) under Article 401 of the Polish Commercial Companies Code. It requests insertion of an agenda item titled “Changes in the Supervisory Board of the Company” and attaches draft resolutions for dismissing and appointing members of the Supervisory Board. This is not an announcement of final voting results or a full company report but rather pre-meeting materials and draft resolutions intended for circulation to shareholders in connection with the AGM. It thus best fits the Proxy Solicitation & Information Statement category (PSI).
2026-06-02 Polish
3a. Formularz wykonywania prawa głosu przez pełnomocnika - wersja edytowalna
Regulatory Filings
2026-06-02 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.